Table 1.
Demographics of Childhood Asthma Management Program (CAMP) and Severe Asthma Research Program (SARP).
| CAMP | SARP | |||||
|---|---|---|---|---|---|---|
| Good Responders (n = 47) |
Poor Responders (n = 48) |
p-Value | Good Responders (n = 8) |
Poor Responders (n = 11) |
p-Value | |
| Age (mean ± SD) | 9.0 (±2.2) | 8.5 (±2.1) | 0.3 | 50.9 (±9.1) | 43.3 (±6.6) | 0.05 |
| Sex | 0.61 | 1.00 | ||||
| Female | 25 (53.2%) | 23 (47.9%) | 7 (87.5%) | 9 (81.8%) | ||
| Male | 22 (46.8%) | 25 (52.1%) | 1 (12.5%) | 2 (18.2%) | ||
| Ancestry | 0.6 | 1.00 | ||||
| European | 39 (83.0%) | 42 (87.5%) | 5 (62.5%) | 8 (72.7%) | ||
| African | 5 (10.6%) | 4 (8.3%) | 3 (37.5%) | 3 (27.3%) | ||
| Hispanic | 1 (2.1%) | 2 (4.2%) | - | - | ||
| Other | 2 (4.3%) | 0 (0.0%) | - | - | ||
| Asthma severity | 0.61 | 0.10 | ||||
| Mild | 23 (48.9%) | 21 (43.8%) | 3 (37.5%) | 1 (9.1%) | ||
| Moderate | 24 (51.1%) | 27 (56.2%) | 2 (25.0%) | 1 (9.1%) | ||
| Severe | - | - | 3 (37.5%) | 9 (81.8%) | ||
| Body mass index (mean ± SD) | 18.1 (±2.8) | 18.0 (±2.9) | 0.9 | 34.9 (±8.2) | 35.3 (±8.3) | 0.90 |
|
Baseline serum IgE level (kU/L, median ± IQR) |
230.0 (±310.0) | 150.0 (±236.0) | 0.3 | 205.0 (±396.0) | 36.0 (±195.0) | 0.09 |
|
Baseline serum eosinophil count (cells/µL, median ± IQR) |
493.0 (±481.0) | 390.0 (±400.0) | 0.1 | 244.0 (±220.0) | 172.0 (±77.0) | 0.08 |
| Baseline PC20 (median ± IQR) | 0.6 (±1.0) | 1.1 (±1.7) | 0.05 | 0.4 (±0.0) | 1.5 (±0.8) | 0.50 |
|
Pre-treatment FEV1 % predicted (mean ± SD) |
86.0% (±15.2%) | 99.8% (±14.1%) | <0.001 | 72.5% (±22.5%) | 82.7% (±11.9%) | 0.20 |
|
Post-treatment FEV1 % predicted (mean ± SD) |
101.0% (±11.5%) | 100.5% (±15.1%) | 0.8 | 76.5% (±23.6%) | 73.6% (±17.9%) | 0.80 |
|
Pre-treatment FEV1/FVC (mean ± SD) |
75.1% (±9.9%) | 80.8% (±7.4%) | 0.002 | 70.4% (±11.0%) | 75.8% (±8.6%) | 0.20 |
|
Post-treatment FEV1/FVC (mean ± SD) |
82.0% (±6.5%) | 81.5% (±8.3%) | 0.7 | 71.6% (±9.2%) | 73.0% (±9.2%) | 0.80 |